Track Lantheus Holdings, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lantheus Holdings, Inc. LNTH · Stock Open Lantheus Holdings, Inc. in new tab

101.59 USD
P/E
25.03
EPS
4.02
P/B
4.85
ROE
21.81
Beta
0.03
Target Price
106.99 USD
Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc.

🧾 Earnings Recap – Q1 2026

Lantheus’ shares rose 8.0% following a quarter marked by better-than-expected commercial execution and meaningful regulatory progress, supporting confidence in the company’s focused radio diagnostics strategy and growth trajectory.

  • PYLARIFY U.S. volumes grew approximately 5.8% year-over-year, holding stable net ASPs despite competitive pressures.
  • FDA approval of PYLARIFY TRUVU, a manufacturing-optimized formulation, positions Lantheus to increase supply and geographic reach starting in Q4.
  • Positive regulatory developments include tentative FDA approval for PNT2003 (radio equivalent to Lutathera) and upcoming PDUFA for MK-6240, a tau-targeted PET diagnostic slated for August.
  • Continued focus on commercial execution in oncology, neurology, and cardiology drove solid volume growth across core products.
  • The CEO search advances with strong internal alignment to maintain disciplined capital allocation and long-term pipeline prioritization.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E25.03
EPS4.02
Book Value20.74
Price to Book4.85
Debt/Equity46.05
% Insiders1.731%
Growth
Revenue Growth0.02%
Earnings Growth-0.20%
Estimates
Forward P/E15.52
Forward EPS6.48
Target Mean Price106.99

DCF valuation

Model fair value for Lantheus Holdings, Inc. (LNTH)
Result
Sign in to run the valuation for LNTH.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus None · mean target 106.99 USD (low 102.50, high 115.00) · as of 9 Nov 2026
Low 102.50
Mean 106.99
High 115.00
Price 101.59
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Lantheus Holdings, Inc. Logo Lantheus Holdings, Inc. Analysis (LNTH)

United States Health Care Official Website Stock

Is Lantheus Holdings, Inc. a good investment? Lantheus Holdings, Inc. (LNTH) is currently trading at 101.59 USD. Market analysts have a consensus price target of 106.99 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 25.03. This valuation is generally in line with the broader market.

Earnings Schedule: Lantheus Holdings, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 6.48.

Investor FAQ

Does Lantheus Holdings, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lantheus Holdings, Inc.?

Lantheus Holdings, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 4.02.

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Exchange Ticker
NGM (Sweden) LNTH
FRA (Germany) 0L8.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion